These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32497550)

  • 21. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of the KRAS
    Loos NHC; Retmana IA; Rijmers J; Wang Y; Gan C; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
    Biomed Pharmacother; 2023 Oct; 166():115304. PubMed ID: 37586117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study.
    Sabet Z; Vagiannis D; Budagaga Y; Zhang Y; Novotná E; Hanke I; Rozkoš T; Hofman J
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.
    Wang JQ; Wang B; Lei ZN; Teng QX; Li JY; Zhang W; Ji N; Cai CY; Ma LY; Liu HM; Chen ZS
    Eur J Pharmacol; 2019 Nov; 863():172611. PubMed ID: 31476282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
    Fernandes E Silva E; Figueira FS; Cañedo AD; Machado KS; Salgado MTSF; Silva TK; Wagner EF; Mattozo FH; Lima ÉA; Sales-Neto JM; Ferreira VU; Comitre AA; Mascarenhas SR; Kalil SJ; Votto APS
    Biomed Pharmacother; 2018 Oct; 106():532-542. PubMed ID: 29990841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
    Hsiao SH; Lusvarghi S; Huang YH; Ambudkar SV; Hsu SC; Wu CP
    Cancer Lett; 2019 Mar; 445():34-44. PubMed ID: 30639533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lansoprazole (LPZ) reverses multidrug resistance (MDR) in cancer through impeding ATP-binding cassette (ABC) transporter-mediated chemotherapeutic drug efflux and lysosomal sequestration.
    Ji N; Li H; Zhang Y; Li Y; Wang P; Chen X; Liu YN; Wang JQ; Yang Y; Chen ZS; Li Y; Wang R; Kong D
    Drug Resist Updat; 2024 Sep; 76():101100. PubMed ID: 38885537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
    Meneses-Lorente G; Fowler S; Guerini E; Kowalski K; Chow-Maneval E; Yu L; Mercier F; Ullah M; Umehara K; Brink A; Buchheit V; Zwanziger E; Phipps A; Djebli N
    Invest New Drugs; 2022 Feb; 40(1):68-80. PubMed ID: 34417912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of ABCB1-related multidrug resistance by ERK5-IN-1.
    Wang F; Li D; Zheng Z; Kin Wah To K; Chen Z; Zhong M; Su X; Chen L; Fu L
    J Exp Clin Cancer Res; 2020 Mar; 39(1):50. PubMed ID: 32164732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
    Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
    Wu CP; Hung TH; Lusvarghi S; Chu YH; Hsiao SH; Huang YH; Chang YT; Ambudkar SV
    Biochem Pharmacol; 2021 Jun; 188():114516. PubMed ID: 33713643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
    Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor.
    Cai CY; Zhang W; Wang JQ; Lei ZN; Zhang YK; Wang YJ; Gupta P; Tan CP; Wang B; Chen ZS
    Biochem Pharmacol; 2020 May; 175():113848. PubMed ID: 32044354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo.
    Budagaga Y; Sabet Z; Zhang Y; Novotná E; Hanke I; Rozkoš T; Hofman J
    Biochem Pharmacol; 2023 Oct; 216():115769. PubMed ID: 37634597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression.
    Liao D; Zhang W; Gupta P; Lei ZN; Wang JQ; Cai CY; Vera AA; Zhang L; Chen ZS; Yang DH
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31801248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells.
    Zhang DM; Li YJ; Shu C; Ruan ZX; Chen WM; Yiu A; Peng YH; Wang J; Lan P; Yao Z; Fung KP; Fu LW; Chen ZS; Ye WC
    Anticancer Drugs; 2013 Jun; 24(5):441-54. PubMed ID: 23466650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
    Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
    Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.